Who should be tested for genetically elevated cholesterol, or familial hypercholesterolemia? And how do we decide when and how to treat? Host Dr. Alan Brown talks with Dr. Jennifer G. Robinson, director of the Lipid Research Clinic and co-director of the Prevention Intervention Center at the University of Iowa. They discuss who is at risk in families, what age to start testing children, as well as treatment guidelines for children, adolescents, adult men, and women before and after childbearing age. For example, how do we treat children who test positive for familial hypercholesterolemia as young as two years of age?
Familial Hypercholesterolemia: Risk Stratifications in Practice
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Who should be tested for genetically elevated cholesterol, or familial hypercholesterolemia? And how do we decide when and how to treat? Host Dr. Alan Brown talks with Dr. Jennifer G. Robinson, director of the Lipid Research Clinic and co-director of the Prevention Intervention Center at the University of Iowa. They discuss who is at risk in families, what age to start testing children, as well as treatment guidelines for children, adolescents, adult men, and women before and after childbearing age. For example, how do we treat children who test positive for familial hypercholesterolemia as young as two years of age?
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
MinuteCE®
I'm Getting the Hang of This! I Have Two Patients: One At 'Indeterminate Risk' and One At 'High Risk' for Clinically Significant Fibrosis
1.00 credits
<p>I'm Getting the Hang of This! I Have Two Patients: One At 'Indeterminate Risk' and One At 'High Risk' for Clinically Significant Fibrosis</p>
MinuteCE®
M3: Managing the Cardiometabolic Risk in MASH
1.00 credits
<p><span data-contrast="auto" xml:lang="EN-US">M3: Managing the Cardiometabolic Risk in MASH</span><span data-ccp-props='{"201341983":0,"335559739":160,"335559740":259}'> </span></p>
MinuteCE®
Maximizing Adherence and Persistence via Patient Engagement
1.25 credits
<p>Maximizing Adherence and Persistence via Patient Engagement</p>
CME/CE
Best Practices for Identifying, Diagnosing and Treating Transthyretin Amyloidosis (ATTR-PN and ATTR-CM)
0.50 credits
<p>Best Practices for Identifying, Diagnosing and Treating Transthyretin Amyloidosis (ATTR-PN and ATTR-CM)</p>
MinuteCE®
HF Management for Patients with Comorbid Conditions
0.75 credits
<p>HF Management for Patients with Comorbid Conditions</p>
MinuteCE®
Level Up Your Skills: Tailoring Management of HF
0.75 credits
<p>Level Up Your Skills: Tailoring Management of HF</p>
MinuteCE®
Clinical Conundrums in ARIA: 1. Navigating the Baseline MRI for Anti-Aβ Monoclonal Antibodies
1.25 credits
<p>Clinical Conundrums in ARIA: Navigating the Baseline MRI for Anti-Aβ Monoclonal Antibodies</p>
MinuteCE®
Clinical Conundrums in ARIA: Communicating ARIA Risk with Patients Considering Anti-Aβ Therapy
1.25 credits
<p>Clinical Conundrums in ARIA: Communicating ARIA Risk with Patients Considering Anti-Aβ Therapy</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?